Amgen Stock Tumbles as Daily Volume Slides to 215th in Liquidity Rankings Amid Strategic Expansion and Market Volatility

On August 22, 2025, Amgen (AMGN) closed with a 0.69% decline, trading at a daily volume of $0.48 billion, ranking 215th among stocks by liquidity. The biotech giant’s shares faced downward pressure amid mixed market conditions, though volume levels remained above its 30-day average.

Recent developments highlighted Amgen’s strategic focus on expanding its oncology portfolio. The company announced preliminary data from a Phase II trial for its experimental therapy targeting solid tumors, showing promising efficacy in a subset of patients. Analysts noted the results, while emphasizing the need for larger-scale validation before commercial implications crystallize.

Regulatory updates also influenced sentiment. A revised FDA guidance on biosimilar pathways was interpreted as favorable for Amgen’s long-term revenue stability, particularly for its flagship product, Enbrel. However, near-term pricing pressures in Medicare negotiations continued to weigh on investor optimism, with industry observers cautioning about broader sector headwinds.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in a moderate return. The total profit from this strategy, considering the given time frame from 2022 to the present, is $2,550. The cumulative return reaches 255%, with a maximum drawdown of -22.3%. This indicates a volatile but ultimately profitable trajectory, with the strategy benefiting from market fluctuations over the period.